rofecoxib has been researched along with Carcinoma, Epidermoid in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with squamous cell carcinoma of the head and neck preoperatively received a specific COX-2 inhibitor (rofecoxib, 25 mg daily) orally for 3 weeks." | 1.34 | Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. ( Andratschke, M; Bergmann, C; Lang, S; Lauffer, L; Lebeau, A; Loehr, I; Mack, B; Moosmann, A; Tiwari, S; Whiteside, TL; Zeidler, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lang, S | 2 |
| Lauffer, L | 2 |
| Clausen, C | 1 |
| Löhr, I | 1 |
| Schmitt, B | 1 |
| Hölzel, D | 1 |
| Wollenberg, B | 1 |
| Gires, O | 1 |
| Kastenbauer, E | 1 |
| Zeidler, R | 2 |
| Tiwari, S | 1 |
| Andratschke, M | 1 |
| Loehr, I | 1 |
| Bergmann, C | 1 |
| Mack, B | 1 |
| Lebeau, A | 1 |
| Moosmann, A | 1 |
| Whiteside, TL | 1 |
| Gridelli, C | 1 |
| Gallo, C | 1 |
| Ceribelli, A | 1 |
| Gebbia, V | 1 |
| Gamucci, T | 1 |
| Ciardiello, F | 1 |
| Carozza, F | 1 |
| Favaretto, A | 1 |
| Daniele, B | 1 |
| Galetta, D | 1 |
| Barbera, S | 1 |
| Rosetti, F | 1 |
| Rossi, A | 1 |
| Maione, P | 1 |
| Cognetti, F | 1 |
| Testa, A | 1 |
| Di Maio, M | 1 |
| Morabito, A | 1 |
| Perrone, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polycht With Cispatin and Gemcitabine and Fixed Dose Rate Infusion of Gem in Association With Cisplatin in 1st-line for Advanced NSCLC[NCT00385606] | Phase 2/Phase 3 | 400 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for rofecoxib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2007 |
2 other studies available for rofecoxib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Cell Movement; Cyclooxyg | 2003 |
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Adhesion; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2007 |